Is Wall Street Bullish or Bearish on Moderna Stock?

Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines. Valued at a market cap of $18.4 billion, the company is best known for its global impact during the COVID-19 pandemic with its vaccine, Spikevax, and has since expanded its commercial portfolio with various other vaccines and medicines. 

This biotechnology company has notably outperformed the broader market over the past 52 weeks. Shares of Moderna have rallied 99.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 28.5%. Moreover, on a YTD basis, the stock is up 65.5%, compared to SPX’s 6% rise.